Consolidated Statement of Profit or Loss

For the year ended 31 March 2024

| | 2024 US\$ million | 2023 US\$ million |
|---|----------------------|----------------------|
| Revenue | 2,145.7 | 2,241.7 |
| Cost of sales | (1,510.8) | (1,608.0) |
| Gross profit | 634.9 | 633.7 |
| Other net (expenses) / income | (0.7) | 1.7 |
| Selling and distribution costs | (278.4) | (294.0) |
| Administrative and other operating expenses | (77.9) | (77.6) |
| Research and development expenses | (81.7) | (83.3) |
| Operating profit | 196.2 | 180.5 |
| Net finance expense | (4.9) | (12.0) |
| Profit before taxation | 191.3 | 168.5 |
| Taxation | (24.7) | (19.3) |
| Profit for the year and attributable to shareholders of the Company | 166.6 | 149.2 |
| Earnings per share (US cents) | | |
| – Basic | 66.0 | 59.1 |
| – Diluted | 65.9 | 59.1 |

Consolidated Statement of Profit or Loss and Other Comprehensive Income

For the year ended 31 March 2024

| | 2024 US\$ million | 2023 US\$ million |
|--|----------------------|----------------------|
| Profit for the year | 166.6 | 149.2 |
| Other comprehensive income for the year | | |
| Item that will not be reclassified to profit or loss: | | |
| Effect of remeasurement of net assets on defined benefit scheme, net of deferred tax | 0.5 | (2.0) |
| | 0.5 | (2.0) |
| Items that may be reclassified subsequently to profit or loss: | | |
| Fair value gains on hedging, net of deferred tax | 2.0 | 0.4 |
| Realisation of hedging reserve, net of deferred tax | (0.9) | (2.5) |
| Exchange translation differences | (9.9) | (20.5) |
| | (8.8) | (22.6) |
| Other comprehensive income for the year | (8.3) | (24.6) |
| Total comprehensive income for the year | 158.3 | 124.6 |